Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2018 / Articles / Feb / What’s in a (Brand) Name?
Business & Regulation Business Practice Trends & Forecasts

What’s in a (Brand) Name?

Do patients care about your brand? Not as much as they care about your outcomes

By Roisin McGuigan 02/15/2018 1 min read

Share

Pharma and healthcare companies spend billions (1) on marketing and promoting their brand – but it may not always be worth it, according to a recent patient survey. The global professional services company Accenture Life Sciences quizzed 8,000 patients from the US, UK, France and Germany on their attitudes to brand loyalty and treatment decisions. Perhaps unsurprisingly, they found that the vast majority of patients (69 percent) consider the benefits of a product more important than its brand. But on the other hand, 25 percent of patients – a significant number – did rate brand loyalty or popularity as a top factor in their healthcare decisions. Other important factors for patients when considering treatment choice were their relationship with their doctor (66 percent), the ability to maintain their current lifestyle (55 percent) and ease of access to care (53 percent). Of the 14 factors in the survey, product brand came in 12th.

The Accenture survey authors, Jim Cleffi and Boris Bogdan, suggest some key things to bear in mind when launching a new product.

Bring an outcome to market, not just a product
Begin focusing on outcomes at the clinical trial stage, and focus on launching evidence-based solutions rather than just products. Use this mindset to inform your launch strategies and commercialization plans.
When you launch a product, lead with the evidence
Demonstrate that your product can provide better outcomes, and consider how you can best communicate this to different patients – what evidence matters, and to who? Data-sharing and analytics are crucial to understand what and how to communicate with healthcare providers and patients. Also, remember that patients might not speak your “language” – speak to patients in a relevant and understandable way.

Tailor your product launches to match the needs, preferences and motivations of patient sub-segments, considering factors such as, geography and the specific disease
Consider who your patient is; for example, younger patients are generally more likely to switch if they think there is a better option available, whereas many baby boomers reported that their treatment decisions are affected by a lack of knowledge about what’s available. The location of patients has just as much impact as their age, making local launch teams are crucial.
Consider whether allocation of resources is optimal
The authors also question whether some of the resources and expenditure currently dedicated to brand promotion might be better used to fund things that really matter more to patients, such as more real world evidence for your product, or patient access programs. “Our research makes it abundantly clear that product launch strategies must evolve from one-size-fits-all approaches,” says Accenture Life Sciences Managing Director Boris Bogdan. “Understanding  how patient sub-segments behave differently will fundamentally shift promotional decision-making and the development of supporting services.”

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. Kantar Media, eMarketer calculations. Accenture, “Product launch: the patient has spoken”, (2018). Available at: http://bit.ly/pharmabranding. Accessed February 1, 2018.

About the Author(s)

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as a Deputy Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

More Articles by Roisin McGuigan

False

Advertisement

Recommended

False

Related Content

What Trump’s Latest Moves Mean for the Industry
Business Practice Standards & Regulation Trends & Forecasts Bioprocessing - Upstream & Downstream
What Trump’s Latest Moves Mean for the Industry

May 27, 2025

6 min read

Audrey Greenberg’s latest insight on US-based manufacturing, Trump’s “Administration for A Healthy America”, and an ever-shifting regulatory environment.

Big Bad Pharma?
Business Practice Trends & Forecasts
Big Bad Pharma?

December 1, 2014

0 min read

The Ebola media frenzy has reminded the public how selfish our industry is. But, somehow, that doesn’t sound quite right...

Access All Areas
Business Practice Trends & Forecasts
Access All Areas

December 1, 2014

0 min read

The 2014 Access to Medicine index shows progress – but companies remain “conservative”

Care to ‘Patent Dance’?
Business Practice Trends & Forecasts
Care to ‘Patent Dance’?

December 1, 2014

0 min read

Amgen accuses Sandoz of snubbing its advances in a complex biosimilar dispute

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.